Lentiviral hepatitis B pseudotype entry requires NTCP and additional hepatocyte-specific factors.

Date publication

octobre 2015

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas

Tous les auteurs :
Meredith LW, Hu K, Cheng X, Howard CR, Baumert TF, Balfe P, van de Graaf KF, Protzer U, McKeating JA

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26474824

Résumé

Hepatitis B virus (HBV) is one of the world's major unconquered infections, resulting in progressive liver disease and current treatments rarely cure infection. A major limitation to discovering new therapies is our limited knowledge of HBV entry and dissemination pathways that hinders the development of in vitro culture systems. To address this gap in our understanding we optimised the genesis of infectious lentiviral pseudoparticles (HBVpp). The recent discovery that the bile salt transporter NTCP acts as a receptor for HBV enabled us to assess the receptor dependency of HBVpp infection. HBVpp preferentially infect hepatoma cells expressing NTCP, whereas other non-liver cells engineered to express NTCP do not support infection, suggesting that additional hepatocyte-specific factors are required for HBVpp internalisation. These results highlight the value of the HBVpp system to dissect the pathways of HBV entry and dissemination.

Référence

J Gen Virol. 2015 Oct 16